Pneumococcal Infectious Disease
12
4
6
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Clinical Trial of PCV24 in Adults Aged ≥18 Years
Clinical Trial of PCV24 in Infants Aged 2-23 Months
Clinical Trial of PCV24 in Children Aged 2-17 Years
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
Clinical Trial of PCV24 in Adults
Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older